Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Susvimo
Pharma
Vabysmo soars as Roche grows through COVID sales declines
Vabysmo grew its market share since August despite Regeneron winning an FDA go-ahead for its high-dose Eylea, according to Swiss drugmaker Roche.
Angus Liu
Feb 1, 2024 11:36am
Roche touts Vabysmo toe-to-toe data against Eylea in RVO
Oct 27, 2022 10:55am
Roche has run into a problem with its new eye med Susvimo
Oct 18, 2022 9:40am
Roche's Susvimo struggles for traction with eye doctors
May 11, 2022 12:08pm
With fewer doses, Genentech's Vabysmo looks to challenge Eylea
Jan 31, 2022 9:28am